Centre Hospitalier Universitaire Amiens-Picardie

Futó vizsgálatok

• Még nem toboroz

  A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

  NCT07915219· 3. fázis· Boehringer Ingelheim· Forrás

• Még nem toboroz

  Safety and Efficacy of a STOPping Strategy Versus Classical Maintenance Dose of JAK Inhibitors in Deep Remission Patients With Ulcerative Colitis

  NCT07718529· 4. fázis· Assistance Publique Hopitaux De Marseille· Forrás

• Még nem toboroz

  Analysis of histological risk factors and biomarkers in paediatric retinoblastoma

  2024-515962-15-00· 2. fázis· Institut Curie· Forrás

• Még nem toboroz

  FirST Lines of Biologics in pAtients With ulceRaTivE Colitis: a Randomised Controlled Trial

  NCT07576452· 4. fázis· University Hospital, Clermont-Ferrand· Forrás

• Még nem toboroz

  A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma

  NCT07612787· 1/2. fázis· Centre Hospitalier Universitaire de Saint Etienne· Forrás

• Még nem toboroz

  FILOCLL017 - NEVOTAL : Nemtabrutinib in addition to Venetoclax-Obinutuzumab in chronic lymphocytic leukemia (CLL) / small lymphocytic leukemia (SLL) patients with TP53 ALterations

  2026-525763-40-00· 2. fázis· French Innovative Leukemia Organization (F.I.L.O.).· Forrás

• Még nem toboroz

  Efficacy of Upadacitinib Re-induction Therapy in Patients With Ulcerative Colitis Who Lost Response to 30 mg Maintenance Dose

  NCT07700446· 4. fázis· Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives· Forrás

• Még nem toboroz

  A pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to Metabolic dysfunction-associated steatohepatitis (MASH)

  2026-525755-82-00· 3. fázis· Glaxosmithkline Research & Development Limited· Forrás

• Még nem toboroz

  A study to investigate safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis (stage F4 fibrosis) due to MASH (NEBULA-2)

  2026-525757-37-00· 3. fázis· Glaxosmithkline Research & Development Limited· Forrás

• Még nem toboroz

  Clinical, Electrophysiological and Genetic Characteristics of Hereditary and Inflammatory Polyneuropathies in France

  NCT07851844· Assistance Publique - Hôpitaux de Paris· Forrás

• Toboroz

  Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse

  NCT07871864· 3. fázis· Gustave Roussy, Cancer Campus, Grand Paris· Forrás

• Még nem toboroz

  ACetazolamide in Patients With Heart Failure, to Decrease Weight and relIEVE Symptoms.

  NCT07737964· 3. fázis· University Hospital, Montpellier· Forrás

• Toboroz

  Optimized Cardiopulmonary Bypass Flow Strategy Based on Ideal Body Weight in Obese Patients Undergoing Cardiac Surgery

  NCT07917494· Centre Hospitalier Universitaire, Amiens· Forrás

• Toboroz

  Evaluating Aganirsen Eye Drops to Reduce the Number of Aflibercept Injections in Wet Age-Related Macular Degeneration Patients.

  2026-526775-27-00· 2. fázis· Laboratoires Kol· Forrás

• Toboroz

  Feasibility of the Application of a new Six-month Treatment for multidrug-resistant tuberculosis (MDR-TB) patients in France (FAST-MDR)

  2024-512763-32-00· 3. fázis· Assistance Publique Hopitaux De Paris· Forrás

• Még nem toboroz

  Obinutuzumab for Systemic Lupus Erythematosus Pure Membranous Nephropathy: a Phase II Trial

  NCT07721363· 2. fázis· Assistance Publique - Hôpitaux de Paris· Forrás

• Még nem toboroz

  Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL).

  NCT07624799· 2. fázis· French Innovative Leukemia Organisation· Forrás

• Még nem toboroz

  Reduction of treatment after Complete Response in Advanced Hormone-Sensitive Breast Cancer

  2026-526319-12-00· 3. fázis· Unicancer· Forrás

• Még nem toboroz

  OBINUSS - A trial to evaluate a new drug in systemic sclerosis: obinutuzumab.

  2025-524003-68-00· 2. fázis· Assistance Publique Hopitaux De Paris· Forrás

• Még nem toboroz

  Evaluation of the Efficacy of Iloprost in the Management of Vaso-occlusive Crises in Adult Patients With Sickle Cell Disease

  NCT07498309· 3. fázis· University Hospital, Rouen· Forrás

• Még nem toboroz

  Prospective evaluation of response to treatment by analysis of measurable residual disease in younger adult patients (18-60 years) with acute myeloid leukemia (AML). The Backbone InterGroup (BIG)-2 umbrella trial from the Acute Leukemia French Intergroup (ALFA, FILO) - BIG2

  2026-525759-96-00· 4. fázis· Centre Hospitalier Universitaire De Toulouse· Forrás

• Még nem toboroz

  Impact of discontinuation of long-term macrolides in stable Non Cystic Fibrosis Bronchiectasis : a multicenter randomized controlled trial

  2025-521493-33-00· 3. fázis· Centre Hospitalier Intercommunal Creteil· Forrás

• Toboroz

  Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome

  NCT07247162· 4. fázis· RECORDATI GROUP· Forrás

• Toboroz

  A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis

  NCT07720375· 2. fázis· UCB Biopharma SRL· Forrás

• Toboroz

  Personalizing chemotherapy selection after surgery for patients with stage III colorectal cancer using a blood test

  2025-521045-24-00· 3. fázis· Unicancer· Forrás

• Toboroz

  Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform)

  2023-505575-69-01· 3. fázis· Institut Gustave Roussy· Forrás

• Toboroz

  PRODIGE 104 – NEOPREDICT A multicenter phase II trial using transcriptomic signatures to personalize neoadjuvant chemotherapy for patients with resectable borderline pancreatic adenocarcinoma.

  2024-519753-11-00· 2. fázis· Fondation Franc.Cancerologie Digestive· Forrás

• Toboroz

  A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis

  NCT07516951· 2. fázis· Chiesi Farmaceutici S.p.A.· Forrás

• Toboroz

  Postoperative Pain Trajectories After Endometriosis Surgery

  NCT07882498· Centre Hospitalier Universitaire, Amiens· Forrás

• Toboroz

  A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma

  2025-523815-12-00· 3. fázis· Janssen Cilag International· Forrás

• Toboroz

  Phase II study of ficerafusp alfa in combination with nivolumab in patients with platinum-refractory head and neck squamous cell carcinoma who progressed within 6 months of multimodality therapy for locally advanced disease.

  2025-521437-88-00· 2. fázis· Groupe Oncologie Radiotherapie Tete Cou· Forrás

• Toboroz

  A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

  NCT07581002· 2/3. fázis· AbbVie· Forrás

• Toboroz

  Optimal Care With Guselkumab in Crohn's Disease / OPTIM Study A Prospective Open Label Interventional, Multicenter Study

  NCT07616687· 4. fázis· Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives· Forrás

• Felfüggesztve

  A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age With Non-Cystic Fibrosis Bronchiectasis

  NCT07547436· 2. fázis· Sanofi· Forrás

• Még nem toboroz

  A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL

  2024-516570-30-00· 2. fázis· Centre Hospitalier De Versailles· Forrás

• Toboroz

  Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year

  2025-521590-13-00· 3. fázis· Janssen Cilag International· Forrás

• Toboroz

  A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

  NCT07357727· 3. fázis· Novartis Pharmaceuticals· Forrás

• Toboroz

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07577856· 3. fázis· Janssen Research & Development, LLC· Forrás

• Toboroz

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  NCT07577843· 3. fázis· Janssen Research & Development, LLC· Forrás

• Toboroz

  A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis Suppurativa

  NCT07547813· 2. fázis· Almirall, S.A.· Forrás

• Toboroz

  Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease

  NCT07292012· 4. fázis· Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives· Forrás

• Toboroz

  Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN

  NCT07264075· 3. fázis· Groupe Oncologie Radiotherapie Tete et Cou· Forrás

• Toboroz

  Cohort of Patients With Chronic Myelomonocytic Leukemia

  NCT07512882· Gustave Roussy, Cancer Campus, Grand Paris· Forrás

• Toboroz

  Evaluation of postoperative recovery when combining intravenous lidocaine with ropivacaine infiltration in laparoscopic colorectal oncologic surgery: a randomized controlled trial

  2025-523207-29-00· 4. fázis· Centre Hospitalier Universitaire Amiens Picardie· Forrás

• Toboroz

  A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

  NCT07419295· 3. fázis· Merck Sharp & Dohme LLC· Forrás

• Toboroz

  A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT07499232· 3. fázis· Janssen Research & Development, LLC· Forrás

• Toboroz

  A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis

  2025-521546-23-00· 3. fázis· Novartis Pharma AG· Forrás

• Toboroz

  Trial assessing fianlimab plus cemiplimab plus chemotherapy or cemiplimab plus chemotherapy in patients with pleural mesothelioma

  2024-519208-29-00· 2. fázis· Intergroupe Francophone De Cancerologie Thoracique· Forrás

• Még nem toboroz

  Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01)

  NCT07337447· 2. fázis· Hospices Civils de Lyon· Forrás

• Toboroz

  A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

  NCT07326709· 3. fázis· Novartis Pharmaceuticals· Forrás

Showing 50 of 269.

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Gyermekkori daganatok22 toboroz
• Crohn-betegség14 toboroz
• Vastagbélrák10 toboroz
• Akut mieloid leukémia (AML)9 toboroz
• Fej-nyaki daganatok8 toboroz
• Szívelégtelenség8 toboroz
• Bronchiectasis7 toboroz
• Máj- és epeúti rák7 toboroz
• Zsírmáj (MASLD/MASH)7 toboroz
• Áttétes emlőrák6 toboroz
• Colitis ulcerosa6 toboroz
• Mielóma multiplex6 toboroz
• Akut limfoid leukémia (ALL)5 toboroz
• Cisztás fibrózis5 toboroz
• ANCA-asszociált vasculitis4 toboroz
• Elhízás4 toboroz
• Idiopátiás tüdőfibrózis4 toboroz
• Krónikus limfoid leukémia (CLL)4 toboroz
• Krónikus mieloid leukémia (CML)4 toboroz
• Magas vérnyomás4 toboroz
• Neuroendokrin daganatok4 toboroz
• Tripla negatív emlőrák4 toboroz
• Tüdőrák4 toboroz
• Glioblasztóma3 toboroz
• Koszorúér-betegség3 toboroz
• Liver cirrhosis3 toboroz
• Lupus (SLE)3 toboroz
• Mieloproliferatív neopláziák3 toboroz
• Pitvarfibrilláció3 toboroz
• Sclerosis multiplex (SM)3 toboroz
• Szarkóma3 toboroz
• Asztma2 toboroz
• Hólyagrák2 toboroz
• Huntington-kór2 toboroz
• Krónikus obstruktív tüdőbetegség (COPD)2 toboroz
• Krónikus vesebetegség2 toboroz
• Mielodiszplasztikus szindróma (MDS)2 toboroz
• Myocarditis2 toboroz
• Parkinson-kór2 toboroz
• Petefészekrák2 toboroz
• Pikkelysömör2 toboroz
• Stroke (szélütés)2 toboroz
• 2-es típusú cukorbetegség1 toboroz
• Amiloidózis1 toboroz
• Aortic stenosis1 toboroz
• Arthritis psoriatica1 toboroz
• Atópiás dermatitisz (ekcéma)1 toboroz
• Brain aneurysm1 toboroz
• Charcot-Marie-Tooth disease1 toboroz
• Csontritkulás1 toboroz
• Cushing's syndrome1 toboroz
• Dermatomyositis and polymyositis (myositis)1 toboroz
• Diffúz nagy B-sejtes limfóma (DLBCL)1 toboroz
• Endometriózis1 toboroz
• Epilepszia1 toboroz
• Gout1 toboroz
• Gyomor- és nyelőcsőrák1 toboroz
• Hasnyálmirigyrák1 toboroz
• Hidradenitis suppurativa1 toboroz
• Hipertrófiás kardiomiopátia1 toboroz
• Időskori makuladegeneráció1 toboroz
• IgA-nefropátia1 toboroz
• Immune thrombocytopenia (ITP)1 toboroz
• Krónikus gyulladásos demielinizációs polineuropátia (CIDP)1 toboroz
• Melanóma1 toboroz
• Mezotelióma1 toboroz
• Narcolepsy1 toboroz
• Neuroblasztóma1 toboroz
• Osteoarthritis1 toboroz
• Prosztatarák1 toboroz
• Rheumatoid arthritis1 toboroz
• Sarlósejtes vérszegénység1 toboroz
• Sjögren-szindróma1 toboroz
• Skizofrénia1 toboroz
• Szisztémás szklerózis (szkleroderma)1 toboroz
• Tuberkulózis1 toboroz
• Vesedaganat1 toboroz

Lezárt vizsgálatok

• Toboroz

  Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)

  NCT07048262· 2. fázis· CSL Behring· Forrás

• Lezárult

  A multicentre, randomised, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of BP1.4979 in adult patients with essential tremor

  2024-517987-46-00· 2. fázis· Bioprojet Pharma· Forrás

• Toboroz

  The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

  NCT06872892· 3. fázis· Boehringer Ingelheim· Forrás

• Lezárult

  IFM 2020-01 (Isamyp) Efficacity assessment of isatuximab plus pomalidomide and dexamethasone in patients with AL amyloidosis who didn't reach at least a very good partial response with their previous treatment

  NCT05066607· 2. fázis· Intergroupe Francophone Du Myelome· Forrás

• Lezárult

  A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa

  NCT06603077· 2. fázis· Avalo Therapeutics, Inc.· Forrás

• Lezárult

  A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered in participants with PD-L1 ≥ 1% TC Stage IIB, IIIA, or select IIIB (T3N2 only) NSCLC following resection and adjuvant platinum-based chemotherapy

  2023-506696-10-00· 3. fázis· F. Hoffmann-La Roche AG· Forrás

• Lezárult

  A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma

  NCT06261957· 3. fázis· GlaxoSmithKline· Forrás

• Lezárult

  Regorafenib-pembrolizumab vs. TACE/TARE in intermediate-stage HCC beyond up-to-7.

  NCT04777851· 3. fázis· Translational Research In Oncology· Forrás

• Toboroz

  A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

  NCT05509777· 3. fázis· Eli Lilly and Company· Forrás

• Fut, nem toboroz

  MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06132256· 2. fázis· Syndax Pharmaceuticals· Forrás

• Lezárult

  Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)

  NCT06122961· Novo Nordisk A/S· Forrás

• Lezárult

  A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

  NCT05784246· 3. fázis· Eli Lilly and Company· Forrás

• Leállították

  Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib

  NCT05625087· 2. fázis· UNICANCER· Forrás

• Lezárult

  Detection of tumor DNA in the blood of patients receiving standard therapy for hormone receptorpositive (HR+) non-HER2 expressing (HER2-) metastatic breast cancer as a tool to select those who may benefit from the next course of fulvestrant in combination with alpelisib or ribociclib.

  2022-502372-22-01· 2. fázis· Unicancer· Forrás

• Fut, nem toboroz

  A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults

  NCT06047457· 3. fázis· Ipsen· Forrás

• Lezárult

  TRansmural hEaliNg Definition in CroHn's Disease (TRENCH 1)

  NCT05903066· Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives· Forrás

• Lezárult

  Relevance of Isoniazid Dosage in Adults Treated for Tuberculosis

  NCT06054334· Centre Hospitalier Universitaire, Amiens· Forrás

• Lezárult

  Long-term Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis

  NCT05672199· 2. fázis· Amgen Inc.· Forrás

• Lezárult

  Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

  NCT05814627· 3. fázis· AbbVie· Forrás

• Meghívásos bevonás

  Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine

  NCT05707949· 3. fázis· AbbVie· Forrás

• Toboroz

  A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

  NCT05711394· 3. fázis· AbbVie· Forrás

• Lezárult

  A Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors.

  NCT03966651· 1. fázis· Institut Claudius Regaud· Forrás

• Lezárult

  PRODIGE 81-FFCD 2101-TRIPLET: Study evaluating the benefit of adding Ipilimumab to the combination of Atezolizumab and Bevacizumab in patients with hepatocellular carcinoma receiving first-line systemic therapy-

  2022-501217-31-00· 2/3. fázis· Fondation Franc.Cancerologie Digestive· Forrás

• Lezárult

  Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy

  NCT05665348· 2/3. fázis· Federation Francophone de Cancerologie Digestive· Forrás

• Lezárult

  Dupilumab step-down strategy to maintain remission in adult and adolescents patients with atopic dermatitis: a non-inferiority randomized trial

  2022-501179-23-00· 4. fázis· Centre Hospitalier Universitaire De Nantes· Forrás

• Toboroz

  Safety and Efficacy of Itacitinib in Adults With Systemic Sclerosis

  NCT04789850· 2. fázis· Assistance Publique - Hôpitaux de Paris· Forrás

• Lezárult

  ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

  NCT05507216· 3. fázis· Abivax S.A.· Forrás

• Lezárult

  EFFICACY AND SAFETY TRIAL OF EPCORITAMAB WITH OR WITHOUT LENALIDOMIDE AS FIRST LINE THERAPY FOR SUBJECTS WITH DIFFUSE LARGE B-CELL LYMPHOMA.

  2023-504832-16-00· 2. fázis· Genmab A/S· Forrás

• Lezárult

  Ezurpimtrostat autophagy inhibitor in association with Atezolizumab-Bevacizumab in first line treatment of unresectable hepatocellular carcinoma, a phase 2b randomized trial. ABE-LIVER

  NCT05448677· 2. fázis· Centre Hospitalier Universitaire De Grenoble· Forrás

• Lezárult

  Clinical study to investigate the efficacy of botensilimab (AGEN1181) in patients with advanced melanoma refractory to prior checkpoint inhibitor therapy

  2022-500652-37-00· 2. fázis· Agenus Inc.· Forrás

• Lezárult

  Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102)

  NCT05111626· 3. fázis· Amgen Inc.· Forrás

• Lezárult

  Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

  NCT05255991· 3. fázis· United Therapeutics· Forrás

• Lezárult

  Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight

  NCT04306315· 4. fázis· LEO Pharma· Forrás

• Leállították

  Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia

  NCT05079230· 3. fázis· Gilead Sciences· Forrás

• Lezárult

  Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge)

  NCT05030155· 3. fázis· Assistance Publique - Hôpitaux de Paris· Forrás

• Lezárult

  Prospective Observational Study of Filgotinib in Participants With Rheumatoid Arthritis in France

  NCT05323591· Alfasigma S.p.A.· Forrás

• Lezárult

  Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol,is safe and can have an impact on patient quality of life, when given along with other lipid lowering medications.

  2024-511263-28-00· 4. fázis· Novartis Pharma AG· Forrás

• Lezárult

  AcTIVE - ACid tranexamic or Terlipressin for Initial emergency treatment of mild to seVere hEmoptysis: a randomized Trial

  NCT04961528· 3. fázis· Assistance Publique Hopitaux De Paris· Forrás

• Lezárult

  Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasm

  NCT04992949· 2. fázis· French Innovative Leukemia Organisation· Forrás

• Lezárult

  Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

  NCT05052801· 3. fázis· Amgen· Forrás

• Lezárult

  Safety and Efficacy of Efavaleukin Alfa in Subjects with Moderately to Severely Active Ulcerative Colitis

  NCT04987307· 2. fázis· Amgen Inc.· Forrás

• Lezárult

  A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness

  NCT05014672· 2. fázis· Calliditas Therapeutics Suisse SA· Forrás

• Fut, nem toboroz

  VIRTUOSE : Efficiency of Sildenafil on the Absolute Claudication Distance of Peripheral Arterial Disease Patients With Intermittent Claudication.

  NCT03686306· 3. fázis· Rennes University Hospital· Forrás

• Lezárult

  Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

  NCT04971785· 2. fázis· Gilead Sciences· Forrás

• Lezárult

  Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS

  NCT04788615· 3. fázis· Novartis Pharmaceuticals· Forrás

• Lezárult

  A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA

  NCT04822350· Pfizer· Forrás

• Lezárult

  A Multicenter, Randomized, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn’s Disease

  2024-513569-38-00· 2/3. fázis· Arena Pharmaceuticals Inc.· Forrás

• Lezárult

  ASTX727 AND DONOR LYMPHOCYTE INFUSIONS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN VERY HIGH RISK MDS OR AML PATIENTS

  NCT04857645· 2. fázis· Groupe Francophone Des Myelodysplasies· Forrás

• Lezárult

  A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

  NCT04901195· 3. fázis· UCB Biopharma SRL· Forrás

• Lezárult

  A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)

  NCT04865770· 3. fázis· Novo Nordisk A/S· Forrás

Showing 50 of 84.

Betegségek

Betegségek, amelyekről az intézmény publikál vagy amelyekre vizsgálatot futtat.

• Crohn-betegség30 munka · 27 vizsgálat
• Hipertrófiás kardiomiopátia18 munka · 1 vizsgálat